Statement re Possible Offer
02 Março 2009 - 1:15PM
UK Regulatory
TIDMYRK
RNS Number : 1570O
York Pharma plc
02 March 2009
Not for release, publication or distribution in whole or in part, in or into the
United States, Canada,
Australia, Japan or the Republic of Ireland
York Pharma plc
(the "Company")
Statement concerning Possible Offer and Rule 2.10 announcement
The Board of the Company notes the recent movement in the Company's share price
and confirms that the Company has made an approach to a potential offeror which
may or may not lead to an offer being made for the Company. The Board of the
Company, which is being advised by Collins Stewart Europe Limited, wishes to
stress that these discussions are at a very early stage and there can be no
certainty that this approach will lead to an offer being made for the Company.
A further announcement will be made as and when appropriate.
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, the
Company confirms that it has in issue 61,399,715 ordinary shares of 5 pence each
("Ordinary Shares") and, in aggregate, 11,737,772 warrants to subscribe for
ordinary shares in the Company, as follows:
+------------+-----------------+-----------------+------------------+--------------+
| | Date of Issue | Number of | Period of | Exercise |
| | | Ordinary Shares | Warrants | Price per |
| | | | | Ordinary |
| | | | | Share |
| | | | | |
+------------+-----------------+-----------------+------------------+--------------+
| AIM | 16 February | 4,511,737 | Exercisable | 50.00 pence |
| Warrants | 2004 | | until | |
| | | | 16 February | |
| | | | 2012 | |
| | | | | |
+------------+-----------------+-----------------+------------------+--------------+
| Series A | 29 September | 3,410,600 | Exercisable | 44.03 pence |
| Warrants | 2008 | | until | |
| | | | 31 August 2018 | |
| | | | | |
+------------+-----------------+-----------------+------------------+--------------+
| Series B | 29 September | 3,815,435 | Exercisable | 44.00 pence |
| Warrants | 2008 | | until | |
| | | | 29 September | |
| | | | 2013 | |
+------------+-----------------+-----------------+------------------+--------------+
In addition the Company has outstanding US$ 6.0 million subordinated convertible
loan notes constituted on 29 September 2008 (the "Convertible Debentures"). The
Convertible Debentures are repayable on 15 February 2014 and have a coupon of 5%
per annum. The holders of the Convertible Debentures have an option to convert
the principal and interest payable thereunder into Ordinary Shares of the
Company at a subscription price of 44p per share (applying the prevailing dollar
conversion rate as published by the Bank of England on the day immediately prior
to the issue of any such Ordinary Shares). For illustration, conversion of the
principal of the US$ 6.0 million at the current prevailing rate of US$1.4255
would give rise to the issue of 9,566,021 Ordinary Shares. Subject to the
restrictions under the terms of the Debt, the Company may redeem the Convertible
Debentures at any time.
There are no shares held in treasury.
The ISIN reference for the Ordinary Shares is GB00B00QHC86 and the AIM Warrants
is GB00B00QZO27.
=-oo--
+-----------------------------------------+----------+--------------------------+
| Contact: | | |
+-----------------------------------------+----------+--------------------------+
| | | |
+-----------------------------------------+----------+--------------------------+
| Richard Anderson, Chief Executive | | + 44 (0) 1908 764020 |
| Officer | | |
| Ian Miscampbell, Chief Financial | | |
| Officer | | |
| York Pharma plc | | |
+-----------------------------------------+----------+--------------------------+
| | | |
+-----------------------------------------+----------+--------------------------+
| Hugh Field | | + 44 (0) 207 523 8350 |
| Collins Stewart Europe Limited | | |
+-----------------------------------------+----------+--------------------------+
Collins Stewart Europe Limited ("Collins Stewart") which is regulated in the
United Kingdom by The Financial Services Authority is acting for the Company in
relation to the matters described in this announcement and is not advising any
other person, and accordingly will not be responsible to anyone other than the
Company for providing the protections afforded to customers of Collins Stewart
or for providing advice in relation to the matters described in this
announcement.
Dealing disclosure requirements
Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the
"Code"), if any person is, or becomes, "interested" (directly or indirectly) in
1% or more of any class of "relevant securities" of the Company, all "dealings"
in any "relevant securities" of the Company (including by means of an option in
respect of, or a derivative referenced to, any such "relevant securities") must
be publicly disclosed by no later than 3.30pm (London time) on the London
business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared,
unconditional as to acceptances, lapses or is otherwise withdrawn or on which
the "offer period" otherwise ends. If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire an
"interest" in "relevant securities" of the Company, they will be deemed to be a
single person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant
securities" of the Company by the Company or by any of its respective
"associates", must be disclosed by no later than 12.00 noon (London time) on the
London business day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose 'relevant
securities' 'dealings' should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.
"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in price or securities. In
particular, a person will be treated as having an "interest" by virtue of the
ownership or control of securities, or by virtue of any option in respect of, or
derivative referenced to, securities.
Terms in quotation marks are defined in the Code, which can be found on the
Panel's website. If you are in any doubt as to whether or not you are required
to disclose a "dealing" under Rule 8, you should consult the Panel.
This information is provided by RNS
The company news service from the London Stock Exchange
END
OFDCKBKKABKDBNK
York Pharma (LSE:YRK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
York Pharma (LSE:YRK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024